康华生物：公司自2004年成立以来，专注于生物医药领域

Core Viewpoint - Kanghua Biotech has been focused on the biopharmaceutical field since its establishment in 2004, positioning itself as a comprehensive high-tech biopharmaceutical company engaged in research, development, and operations [2] Group 1: Company Overview - The company is the first in China to produce and sell human diploid cell rabies vaccines [2] - Kanghua Biotech has developed multiple innovative vaccine platforms, including mRNA vaccine platform, recombinant protein VLP vaccine platform, polysaccharide-protein conjugate vaccine platform, live attenuated vaccine platform, inactivated vaccine platform, and new vaccine adjuvant platform [2] Group 2: Research and Development - The company is currently working on several innovative vaccine projects, including a hexavalent norovirus vaccine and a herpes simplex virus vaccine [2] - The hexavalent norovirus vaccine has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, classified as a Class 1 innovative vaccine [2] - Kanghua Biotech is actively advancing the product development process and the implementation of research results [2]